雪榕生物：预计2025年净利润2900万元～4000万元 同比扭亏为盈

Core Viewpoint - Snow Rong Biological (300511.SZ) expects a net profit attributable to shareholders of 29 million to 40 million yuan in 2025, marking a turnaround from losses, with a net profit excluding non-recurring gains and losses projected at 5 million to 16 million yuan, also indicating a return to profitability [1] Industry Summary - The edible mushroom industry has undergone a prolonged adjustment period, with expectations for stabilization and recovery in the second half of 2025, driven by an increase in the prices of main products, which will enhance gross margins [1] Company Summary - In the second half of 2025, breakthroughs in new strains of white enoki mushrooms are anticipated, leveraging the company's advantages in seed sources, leading to a significant increase in capacity utilization and a notable reduction in overall costs [1] - The company is actively pursuing quality improvement and efficiency enhancement initiatives, with strict control over expense spending, resulting in a year-on-year reduction of approximately 45 million yuan in period expenses [1] - The expected impact of non-recurring gains and losses on net profit for 2025 is estimated at around 24 million yuan, primarily from government subsidies and asset disposal gains [1]